NASDAQ:RVNC Revance Therapeutics (RVNC) Stock Forecast, Price & News $30.01 -0.26 (-0.86%) (As of 10:39 AM ET) Add Compare Share Share Today's Range$29.91▼$30.8450-Day Range$30.00▼$37.6152-Week Range$11.27▼$37.98Volume116,544 shsAverage Volume1.47 million shsMarket Capitalization$2.52 billionP/E RatioN/ADividend YieldN/APrice Target$42.36 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Revance Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside40.0% Upside$42.36 Price TargetShort InterestBearish17.52% of Shares Sold ShortDividend StrengthN/ASustainability-0.88Upright™ Environmental ScoreNews Sentiment1.46Based on 3 Articles This WeekInsider TradingSelling Shares$8.28 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.78) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.16 out of 5 starsMedical Sector501st out of 1,009 stocksPharmaceutical Preparations Industry240th out of 494 stocks 3.4 Analyst's Opinion Consensus RatingRevance Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.36, Revance Therapeutics has a forecasted upside of 40.0% from its current price of $30.27.Amount of Analyst CoverageRevance Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted17.52% of the outstanding shares of Revance Therapeutics have been sold short.Short Interest Ratio / Days to CoverRevance Therapeutics has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.Change versus previous monthShort interest in Revance Therapeutics has recently increased by 4.92%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRevance Therapeutics does not currently pay a dividend.Dividend GrowthRevance Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRevance Therapeutics has received a 74.80% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Revance Therapeutics is -0.88. Previous Next 3.0 News and Social Media Coverage News SentimentRevance Therapeutics has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Revance Therapeutics this week, compared to 4 articles on an average week.Search Interest9 people have searched for RVNC on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Revance Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Revance Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,283,332.00 in company stock.Percentage Held by InsidersOnly 3.60% of the stock of Revance Therapeutics is held by insiders.Percentage Held by Institutions82.68% of the stock of Revance Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Revance Therapeutics are expected to grow in the coming year, from ($2.78) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Revance Therapeutics is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Revance Therapeutics is -6.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Revance Therapeutics (NASDAQ:RVNC) StockRevance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.Read More Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RVNC Stock News HeadlinesMay 22, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Receives New Coverage from Analysts at StockNews.comMay 21, 2023 | fool.comRevance Therapeutics (NASDAQ: RVNC)May 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 18, 2023 | americanbankingnews.comDustin S. Sjuts Sells 21,015 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) StockMay 18, 2023 | americanbankingnews.comMark J. Foley Sells 70,447 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) StockMay 17, 2023 | americanbankingnews.comRevance Therapeutics, Inc. (NASDAQ:RVNC) SVP Dwight Moxie Sells 21,401 SharesMay 17, 2023 | americanbankingnews.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 16, 2023 | finance.yahoo.comHere’s Why Revance Therapeutics (RVNC) Outperformed in Q1May 31, 2023 | Edge On The Street (Ad)Soaring EV Industry Keeps Investor Focus on LithiumThe need for lithium keeps going up, up, up with the mass adoption of electric vehicles. The lithium demand for EV batteries alone is now double the rate of lithium production.May 14, 2023 | americanbankingnews.comRevance Therapeutics, Inc. to Post Q2 2023 Earnings of ($0.70) Per Share, William Blair Forecasts (NASDAQ:RVNC)May 12, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Shares Gap Down to $37.61May 11, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) PT Raised to $50.00May 10, 2023 | nasdaq.comHC Wainwright & Co. Maintains Revance Therapeutics (RVNC) Buy RecommendationMay 10, 2023 | nasdaq.comNeedham Maintains Revance Therapeutics (RVNC) Buy RecommendationMay 10, 2023 | americanbankingnews.comHC Wainwright Increases Revance Therapeutics (NASDAQ:RVNC) Price Target to $48.00May 9, 2023 | seekingalpha.comRevance Therapeutics GAAP EPS of -$0.74, revenue of $49.3MMay 9, 2023 | finance.yahoo.comThis Botox Rival Has Investors Smiling With A 100% Gain This Year. The Stock Broke Out Today.May 9, 2023 | finance.yahoo.comRevance Reports First Quarter 2023 Financial Results, Provides Corporate UpdateMay 9, 2023 | finance.yahoo.comTop 4 Stocks Set to Beat on Earnings Today After Market ClosesMay 8, 2023 | msn.comEarnings Preview For Revance TherapeuticsMay 7, 2023 | americanbankingnews.comRevance Therapeutics (RVNC) Set to Announce Earnings on TuesdayMay 3, 2023 | reuters.comAllergan accuses Botox rival Revance of employee raiding in US lawsuitMay 3, 2023 | americanbankingnews.comTobin Schilke Sells 3,201 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) StockMay 2, 2023 | finance.yahoo.comRevance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseMay 2, 2023 | finance.yahoo.comRevance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023April 23, 2023 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Rating Reiterated by Needham & Company LLCApril 19, 2023 | msn.comNeedham Reiterates Revance Therapeutics (RVNC) Buy RecommendationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RVNC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RVNC Company Calendar Last Earnings5/09/2023Today5/30/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RVNC CUSIPN/A CIK1479290 Webwww.revance.com Phone(615) 724-7755Fax510-742-3401Employees495Year FoundedN/APrice Target and Rating Average Stock Price Forecast$42.36 High Stock Price Forecast$65.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+40.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-356,420,000.00 Net Margins-224.65% Pretax Margin-224.20% Return on Equity-1,091.00% Return on Assets-58.57% Debt Debt-to-Equity Ratio30.11 Current Ratio4.14 Quick Ratio3.79 Sales & Book Value Annual Sales$132.57 million Price / Sales19.18 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book201.80Miscellaneous Outstanding Shares84,000,000Free Float80,976,000Market Cap$2.54 billion OptionableOptionable Beta0.84 Key ExecutivesMark J. FoleyChief Executive Officer & DirectorDustin S. SjutsPresidentTobin C. SchilkeChief Financial OfficerAzita NejadSenior Vice President-Technical OperationsRoman G. RubioSenior Vice President-Clinical DevelopmentKey CompetitorsSchrödingerNASDAQ:SDGRXenon PharmaceuticalsNASDAQ:XENEMirati TherapeuticsNASDAQ:MRTXInsmedNASDAQ:INSMCorcept TherapeuticsNASDAQ:CORTView All CompetitorsInsiders & InstitutionsProShare Advisors LLCSold 1,950 shares on 5/26/2023Ownership: 0.018%Ameriprise Financial Inc.Bought 46,713 shares on 5/22/2023Ownership: 0.335%International Biotechnology Trust PLCBought 63,000 shares on 5/18/2023Ownership: 0.218%New York State Common Retirement FundSold 10,118 shares on 5/18/2023Ownership: 0.051%Centaurus Financial Inc.Bought 688 shares on 5/18/2023Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions RVNC Stock - Frequently Asked Questions Should I buy or sell Revance Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVNC shares. View RVNC analyst ratings or view top-rated stocks. What is Revance Therapeutics' stock price forecast for 2023? 8 Wall Street research analysts have issued twelve-month price objectives for Revance Therapeutics' shares. Their RVNC share price forecasts range from $26.00 to $65.00. On average, they predict the company's share price to reach $42.36 in the next year. This suggests a possible upside of 40.0% from the stock's current price. View analysts price targets for RVNC or view top-rated stocks among Wall Street analysts. How have RVNC shares performed in 2023? Revance Therapeutics' stock was trading at $18.46 at the start of the year. Since then, RVNC shares have increased by 64.0% and is now trading at $30.27. View the best growth stocks for 2023 here. When is Revance Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our RVNC earnings forecast. How were Revance Therapeutics' earnings last quarter? Revance Therapeutics, Inc. (NASDAQ:RVNC) issued its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.01. The biopharmaceutical company had revenue of $49.33 million for the quarter, compared to analysts' expectations of $46.21 million. Revance Therapeutics had a negative trailing twelve-month return on equity of 1,091.00% and a negative net margin of 224.65%. The business's quarterly revenue was up 95.3% compared to the same quarter last year. During the same quarter last year, the business earned ($0.94) earnings per share. What ETFs hold Revance Therapeutics' stock? ETFs with the largest weight of Revance Therapeutics (NASDAQ:RVNC) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Long Cramer Tracker ETF (LJIM), Invesco DWA Healthcare Momentum ETF (PTH), iShares U.S. Pharmaceuticals ETF (IHE), AdvisorShares Alpha DNA Equity Sentiment ETF (SENT), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Future Gen 200 ETF (QQQS). What is Mark Foley's approval rating as Revance Therapeutics' CEO? 7 employees have rated Revance Therapeutics Chief Executive Officer Mark Foley on Glassdoor.com. Mark Foley has an approval rating of 82% among the company's employees. What other stocks do shareholders of Revance Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO). What is Revance Therapeutics' stock symbol? Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC." Who are Revance Therapeutics' major shareholders? Revance Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Palo Alto Investors LP (6.27%), Thrivent Financial for Lutherans (2.40%), State Street Corp (2.32%), FMR LLC (2.20%), Jennison Associates LLC (1.95%) and Geode Capital Management LLC (1.90%). Insiders that own company stock include Angus C Russell, Aubrey Rankin, Dustin S Sjuts, Dwight Moxie, Mark J Foley and Tobin Schilke. View institutional ownership trends. How do I buy shares of Revance Therapeutics? Shares of RVNC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Revance Therapeutics' stock price today? One share of RVNC stock can currently be purchased for approximately $30.27. How much money does Revance Therapeutics make? Revance Therapeutics (NASDAQ:RVNC) has a market capitalization of $2.54 billion and generates $132.57 million in revenue each year. The biopharmaceutical company earns $-356,420,000.00 in net income (profit) each year or ($4.61) on an earnings per share basis. How many employees does Revance Therapeutics have? The company employs 495 workers across the globe. How can I contact Revance Therapeutics? Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The official website for the company is www.revance.com. The biopharmaceutical company can be reached via phone at (615) 724-7755, via email at jherbert@revance.com, or via fax at 510-742-3401. This page (NASDAQ:RVNC) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.